Nanoplatforms for Delivery of siRNA to the Eye

Kataki, Manjir Sarma; Kakoti, Bibhuti Bhusan; Jameson, Melanie; Solanki, Aum; Hirani, Anjali; Pathak, Yashwant

doi:10.2174/138161282131151013191051

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, in contrast to numerous examples of successful delivery of therapeutic agents to ocular tissues with nanocarrier systems, − the development of polymeric nanomicelles for back of the eye delivery has rarely been addressed. However, such a nanomicellar approach may be desirable, for instance, in case of a drug such as cidofovir, which has lower bioavailability in human ocular tissues following intravenous or intravitreal administration. , …”

Section: Introductionmentioning

confidence: 99%

Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery

Mandal¹,

Cholkar²,

Khurana³

et al. 2017

Mol. Pharmaceutics

View full text Add to dashboard Cite

Topical drug administration for back of the eye delivery is extremely challenging due to the presence of protection mechanisms and physiological barriers. Self-assembled polymeric nanomicelles have emerged as promising vehicles for drug delivery. Apart from serving as an inert nanocarrier for therapeutic agents, polymeric nanomicelles are known to bypass mononuclear phagocytic system (MPS) and efflux transporters thereby improving drug bioavailability. In this investigation, a highly efficacious biotinylated lipid prodrug of cyclic cidofovir (B-C12-cCDF) was formulated within polymeric nanomicelles as a carrier for targeted retinal delivery. Polymeric nanomicelles were prepared from polyoxyethylene hydrogenated castor oil 40 (HCO-40) and octoxynol 40 (OC-40). In vitro release studies revealed that B-C12-cCDF-loaded nanomicelles released B-C12-cCDF at a faster rate in stimulated tear fluid (STF) in comparison to PBST. MTT and LDH assays demonstrated negligible cytotoxicity of B-C12-cCDF-loaded nanomicelles relative to CDF and B-C12-cCDF in HRPE (human retinal pigment epithelial, D407), HCE-T (human corneal epithelial), and CCL 20.2 (human conjunctival epithelial) cells. Confocal laser scanning microscopy and flow cytometry analyses indicated that B-C12-cCDF-loaded nanomicelles were efficiently internalized into D407 and HCE-T cells in contrast to CDF and B-C12-cCDF. Moreover, little B-C12-cCDF was also observed in the nuclei after 24 h of incubation. Polymeric nanomicelles carrying the transporter targeted prodrug did not produce any cytotoxic effects and were internalized into the cells effectively. Permeability experiments across HCE-T cells further confirmed significant transport of prodrug loaded nanomicelles and their subsequent uptake into D407 cells. These findings indicate that HCO-40/OC-40 based polymeric nanomicelles could become a promising topical delivery system for ocular administration of antiviral agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery

Mandal¹,

Cholkar²,

Khurana³

et al. 2017

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The major obstacles for the drug treatments are the presence of a restrictive blood-retina barrier (BRB), which limits the drug entry into ocular tissues and results in undesired irreversible neuronal damage. Recent advances in nanotechnology have revealed that novel nano-platforms are greatly promising in enhancing drug delivery while being intrusive less to the eye systems (Leon et al, 2000;De Jong & Borm, 2008;Kataki et al, 2015). The nanoscale drug-loading system in ophthalmic medication enables effective drug delivery as it can penetrate the BRB and hence, overcome the aforementioned challenges in the ocular disorder therapeutics (Kataki et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

“…Recent advances in nanotechnology have revealed that novel nano-platforms are greatly promising in enhancing drug delivery while being intrusive less to the eye systems (Leon et al, 2000;De Jong & Borm, 2008;Kataki et al, 2015). The nanoscale drug-loading system in ophthalmic medication enables effective drug delivery as it can penetrate the BRB and hence, overcome the aforementioned challenges in the ocular disorder therapeutics (Kataki et al, 2015). It also improves the bioavailability of drugs significantly, reduces the dosage as well as usage frequency of drugs, and enhances the safety and longevity of the drug (De Jong & Borm, 2008).…”

Section: Discussionmentioning

confidence: 99%

Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy

Wang

Gao

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Co-delivery nanoparticles with characteristics of intracellular precision release drug have been generally accepted as an effective therapeutic strategy for eye diseases. In this study, we designed a new codelivery system (miRNA/NP-BRZ) as a lasting therapeutic approach to prevent the neuro-destructive after the long-term treatment of glaucoma. Neuroprotective and intraocular pressure (IOP) response were assessed in in vivo and in vitro models of glaucoma. At the meaning time, we describe the preparation of miRNA/NP-BRZ, drug release characteristics, intraocular tracing, pharmacokinetic and pharmacodynamics study and toxicity test. We found that miRNA/NP-BRZ could remarkably decrease IOP and significantly prevent retinal ganglion cell (RGC) damages. The new formula of miRNA-124 encapsulated in PEG-PSA-BRZ nanoparticles exhibits high encapsulation efficiency (EE), drug-loading capacity (DC), and stable controlled-release efficacy (EC). Moreover, we also verified that the miRNA/NP-BRZ system is significantly neuroprotective and nontoxic as well as lowering IOP. This study shows our co-delivery drug system would have a wide potential on social and economic benefits for glaucoma.

show abstract

“…On the contrary, transfection of cells is currently more efficacious via AAV-vectors than via nanoparticles, but researchers are confident that the easy and diverse modification options of nanoparticles can remedy this deficit in the near future. Instead of carrying plasmid DNA, nanoparticles can likewise carry siRNA to silence specific genes by RNA interference [62]. This method is well suited for the treatment of acute diseases.…”

Section: Gene or Sirna Delivery To The Eye Via Nanotechnologymentioning

confidence: 99%

Untitled

2022

JOCR

View full text Add to dashboard Cite

For about 20 years, nanotechnological applications are intensively investigated in all fields of medicine. In ophthalmology, nanoparticles are of special interest as carrier systems for the targeted delivery of drugs, genes or siRNA to the anterior as well as to the posterior segment of the eye. Above that, sustained drug release plays a major role for the treatment of many ophthalmic diseases and nanoparticles have the potential to perform this task without inducing local adverse reactions.Nanoparticles are primarily defined by their size that has to range below 100 nm. All other characteristics are variable. The large variety of nanoparticle types and the fact, that they are easily modifiable allows their adaption to the task set for them.In this review, we summarize the application of nanoparticles in ophthalmology and describe the current challenges.

show abstract

Nanoplatforms for Delivery of siRNA to the Eye

Cited by 6 publications

References 0 publications

Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery

Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery

Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy

Untitled

Contact Info

Product

Resources

About